中华肝脏病杂志最新文献

{"title":"[Research progress on the applicability of diagnostic criteria for metabolic and alcohol-related liver disease in patients with cirrhosis and after liver transplantation].","authors":"Y Han, H Xu, L Wang","doi":"10.3760/cma.j.cn501113-20260225-00073","DOIUrl":"10.3760/cma.j.cn501113-20260225-00073","url":null,"abstract":"<p><p>Metabolic and alcohol-related liver disease (MetALD) is a key subtype within the new classification system of fatty liver disease, and its diagnosis relies on three core elements: hepatic steatosis, metabolic dysfunction, and alcohol consumption. However, the applicability of current diagnostic criteria is limited in patients with cirrhosis and liver transplant recipients due to structural destruction of the liver, remodeling of metabolic status, and difficulties in accurately assessing alcohol intake. This article systematically reviews the current application of MetALD diagnostic criteria in the above special populations, focusing on the key limitations in clinical evaluation, and explores precision diagnostic strategies including combined biomarker detection and optimization of imaging techniques, aiming to provide a basis for stratified management and prognostic assessment in these patients.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"34 8","pages":"732-737"},"PeriodicalIF":0.0,"publicationDate":"2026-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13529423/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148907381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Exploration of the mechanisms of portal hypertension driven by metabolic disorders in non-cirrhotic stages of metabolic-associated fatty liver disease].","authors":"Y Q Zhao, Y Wang, J J Liu, H You, J J Zhao","doi":"10.3760/cma.j.cn501113-20250507-00175","DOIUrl":"10.3760/cma.j.cn501113-20250507-00175","url":null,"abstract":"<p><p>Portal hypertension (PH) is generally considered a complication of advanced liver fibrosis and cirrhosis in chronic liver disease and is closely associated with poor prognosis. Metabolic-associated fatty liver disease (MAFLD) may develop PH even during the non-cirrhotic stages, suggesting that mechanisms beyond cirrhosis exist that contribute to PH. However, prior research has primarily focused on the characteristics and pathophysiological mechanisms of PH in cirrhosis, while systematic discussions on the occurrence of PH in the non-cirrhotic stage of MAFLD are still not expounded. This article takes the metabolic characteristics as an entry point to systematically analyze the roles and mechanisms of the metabolic microenvironment in the development of PH, providing a basis for effectively preventing the progression of PH in MAFLD.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"34 8","pages":"807-810"},"PeriodicalIF":0.0,"publicationDate":"2026-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13529426/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148907275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Burden and epidemiological trends of alcohol use disorder and alcoholic liver disease in the Asia-Pacific region].","authors":"Q C Zhuang, C Q Yang","doi":"10.3760/cma.j.cn501113-20260528-00212","DOIUrl":"10.3760/cma.j.cn501113-20260528-00212","url":null,"abstract":"<p><p>Alcohol-related diseases represent a major global public health concern, among which alcoholic liver disease and alcohol use disorder are the two most representative categories of alcohol-related health problems. The Asia-Pacific region is characterized by a large population, marked socioeconomic disparities, and diverse drinking cultures. In recent years, the burden of alcohol-related diseases in this region has exhibited significant regional heterogeneity. This article reviews the epidemiological trends, disease burden characteristics, contributing factors, and prevention and control strategies for alcohol-related liver disease in the Asia-Pacific region, with the aim of providing a reference for regionalized and stratified intervention approaches.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"34 8","pages":"718-722"},"PeriodicalIF":0.0,"publicationDate":"2026-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13529424/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148907096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Proportion and clinical characteristics of probable metabolic-associated fatty liver disease-related cirrhosis in cryptogenic cirrhosis].","authors":"Y Wang, Y Deng, Y Jian, J J Liu, Y Q Zhao, X Y Zhao, J J Zhao, H You","doi":"10.3760/cma.j.cn501113-20251229-00552","DOIUrl":"10.3760/cma.j.cn501113-20251229-00552","url":null,"abstract":"&lt;p&gt;&lt;p&gt;&lt;b&gt;Objective:&lt;/b&gt; To explore the likelihood of metabolic-associated fatty liver disease (MAFLD)based on metabolic characteristics and to provide a reference for identifying potential causative factors in patients with cryptogenic cirrhosis. &lt;b&gt;Methods:&lt;/b&gt; A total of 2,190 patients with cirrhosis admitted to the Department of Hepatology, Beijing Friendship Hospital, Capital Medical University, from January 2022 to December 2024 were retrospectively analyzed. 163 patients with cryptogenic cirrhosis following screening by exclusion criteria were finally included. According to the Liver Forum consensus, patients were classified into three groups based on metabolic characteristics: \"very likely\" MAFLD-related cirrhosis, \"possibly\" MAFLD-related cirrhosis, and \"other\" cryptogenic cirrhosis. 151 patients with MAFLD-related cirrhosis served as the control group and were admitted during the same period. Clinical data and prognostic scores were collected and compared among the groups. Logistic regression analysis was used to assess the impact of MAFLD as a potential etiology for prognostic score categories. Normally distributed continuous variables were compared using one-way ANOVA, while non-normally distributed continuous variables were compared using non-parametric tests for overall intergroup analysis. Categorical variables were analyzed using chi-square tests or Fisher's exact tests. Post-hoc pairwise comparisons were conducted when the overall differences were statistically significant. Multiple comparisons were performed for type 1 error control. The Bonferroni correction method was applied to control for type I error in multiple comparisons and p-values. &lt;b&gt;Results:&lt;/b&gt; Among 163 patients with cryptogenic cirrhosis, 57(35.0%) were \"very likely\" MAFLD-related cirrhosis, and 31(19.0%) were \"possibly\" MAFLD-related cirrhosis, both groups totaling 88(54.0%). Compared with the definitive diagnosis group, the \"very likely\" and \"possibly\" groups showed no statistically significant differences in the prevalence rate of overweight/obesity (86.4% &lt;i&gt;vs&lt;/i&gt;. 90.7%), type 2 diabetes mellitus (53.4% &lt;i&gt;vs&lt;/i&gt;. 59.6%), and hyperlipidemia (10.2% &lt;i&gt;vs&lt;/i&gt;. 20.5%) (adjusted &lt;i&gt;P&lt;/i&gt;&gt;0.05), with only a lower prevalence of hypertension (40.9% &lt;i&gt;vs&lt;/i&gt;. 56.3%, adjusted &lt;i&gt;P&lt;/i&gt;=0.044). However, the former group exhibited significantly lower lipid levels at presentation (adjusted &lt;i&gt;P&lt;/i&gt;&lt;0.05), with no significant difference in fasting blood glucose levels (adjusted &lt;i&gt;P&lt;/i&gt;=1.000). Additionally, a higher proportion of patients were in decompensated stages (81.8% &lt;i&gt;vs&lt;/i&gt;. 60.9%, adjusted &lt;i&gt;P&lt;/i&gt;=0.002), with worse liver function and higher risks of adverse prognosis. &lt;b&gt;Conclusion:&lt;/b&gt; Metabolic factors were associated with more than half of the cases of cryptogenic cirrhosis at our hospital. However, lipid and blood glucose abnormalities at the time of consultation were often unremarkable, as these patients had already progressed to the decompensated stag","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"34 8","pages":"778-785"},"PeriodicalIF":0.0,"publicationDate":"2026-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13529429/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148907319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Exploring the efficacy and safety profile of the use of a heparin-free integrated tandem pre-flushing method for DPMAS treatment in patients with liver failure].","authors":"J Zhou, H Yang, Q Wu, F Li, X L Lu, J Q Jiang, X Q Lan, B L Li, Y Li","doi":"10.3760/cma.j.cn501113-20251201-00513","DOIUrl":"10.3760/cma.j.cn501113-20251201-00513","url":null,"abstract":"&lt;p&gt;&lt;p&gt;&lt;b&gt;Objective:&lt;/b&gt; To compare the efficacy and safety profiles of heparin and heparin-free pre-flushing methods in patients with liver failure treated with a double plasma molecular adsorption system (DPMAS). &lt;b&gt;Method:&lt;/b&gt; A prospective, single-center observational study was conducted. Patients with liver failure who received DPMAS treatment at the Liver Disease Center of Nanfang Hospital, Southern Medical University, between October 2024 and February 2025 were consecutively screened for inclusion. The choice of whether to use the heparin pre-flushing method was determined in accordance with the clinicians' clinical experience. Demographic characteristics, treatment-related variables (heparin pre-flush method, adverse events, and pressure parameters), and clinical indicators (liver biochemical parameters, coagulation parameters, and inflammatory markers) were collected before and 48 hours after treatment. Categorical variables were compared using the &lt;i&gt;χ&lt;/i&gt;&lt;sup&gt;2&lt;/sup&gt; test. Inter-group comparisons of continuous variables were performed using &lt;i&gt;t&lt;/i&gt;-tests or non-parametric tests. &lt;b&gt;Result:&lt;/b&gt; Data from 128 patients with liver failure treated with DPMAS were included. The mean age was 44.5 years, with 115 males (89.8%) and 13 females (10.2%). The internal jugular vein was the primary vascular access in both groups. Baseline data showed that coagulation parameters were worse in the heparin-free group than in the heparin group (&lt;i&gt;P&lt;/i&gt;&lt;0.05). After DPMAS treatment, changes were observed in both pre-flushing groups, including total bilirubin (heparin group pre-and post-treatment mean: 381.62 μmol/L &lt;i&gt;vs&lt;/i&gt;. 337.36 μmol/L, &lt;i&gt;P&lt;/i&gt;&lt;0.001; heparin-free group pre-and post-treatment mean: 404 μmol/L &lt;i&gt;vs&lt;/i&gt;. 379 μmol/L, &lt;i&gt;P&lt;/i&gt;=0.022), albumin (heparin group pre-and post-treatment mean: 33.48 g/L &lt;i&gt;vs&lt;/i&gt;. 33.49 g/L, &lt;i&gt;P&lt;/i&gt;=0.056; heparin-free group pre- and post-treatment mean: 31.41 g/L &lt;i&gt;vs&lt;/i&gt;. 32.42 g/L, &lt;i&gt;P&lt;/i&gt;=0.052), prothrombin activity (heparin group pre-and post-treatment median: 41.5% &lt;i&gt;vs&lt;/i&gt;. 42.0%, &lt;i&gt;P&lt;/i&gt;=0.103; heparin-free group pre-and post-treatment median: 33.90% &lt;i&gt;vs&lt;/i&gt;. 32.35%, &lt;i&gt;P&lt;/i&gt;=0.022), C-reactive protein (heparin group pre-and post-treatment median: 13.17 mg/L &lt;i&gt;vs&lt;/i&gt;. 13.32 mg/L, &lt;i&gt;P&lt;/i&gt;=0.004; heparin-free group pre-and post-treatment median: 16.29 mg/L &lt;i&gt;vs&lt;/i&gt;. 19.30 mg/L, &lt;i&gt;P&lt;/i&gt;=0.415), and procalcitonin (heparin group pre-and post-treatment median: 0.783 ng/mL &lt;i&gt;vs&lt;/i&gt;. 0.796 ng/mL, &lt;i&gt;P&lt;/i&gt;=0.598; heparin-free group pre-and post-treatment median: 0.82 ng/mL &lt;i&gt;vs&lt;/i&gt;. 1.15 ng/mL, &lt;i&gt;P&lt;/i&gt;=0.172). Regarding treatment efficacy, there were no statistically significant differences in the magnitude of changes in total bilirubin and albumin before and after treatment between the two pre-flushing methods (&lt;i&gt;P&lt;/i&gt;=0.144, &lt;i&gt;P&lt;/i&gt;=0.843). In terms of safety profile, there were no statistically significant differences in the magnitude of changes in prothrombin time, international normalized ","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"34 8","pages":"786-793"},"PeriodicalIF":0.0,"publicationDate":"2026-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13529431/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148907239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Considerations on clinical trial issues related to new drug development for metabolic and alcohol-associated liver disease and fatty liver disease].","authors":"X Y Wang, H M Sun, Y H Gao","doi":"10.3760/cma.j.cn501113-20260303-00085","DOIUrl":"10.3760/cma.j.cn501113-20260303-00085","url":null,"abstract":"<p><p>The global incidence of alcohol-associated liver disease(ALD) is rising. Beyond glucocorticoids, effective pharmacological therapies for severe ALD remain limited. With the introduction of the novel concept of \"metabolic and alcohol-associated liver disease (MetALD) \", it has emerged as a distinct clinical condition characterized by synergistic liver injury resulting from the interplay between metabolic dysfunction and alcohol consumption. In contrast to the substantial progress in drug development for metabolic associated steatotic liver disease (MASLD), clinical research on ALD and MetALD has advanced slowly. Worldwide, only a limited number of clinical trials for ALD have been registered, and ongoing studies frequently encounter challenges such as patient recruitment difficulties and high attrition rates. Given its recent classification, MetALD currently lacks specific clinical trial guidance from regulatory agencies. These hurdles are compounded by additional challenges, including etiological heterogeneity, stigma related to alcohol use, and suboptimal treatment adherence, which collectively impede therapeutic development. Stratification of study populations according to cardiometabolic risk profiles and stages of liver fibrosis represents a critical strategy to optimize trial design and identify patient subgroups most likely to benefit. This article delineates key challenges in clinical trial design for novel ALD and MetALD therapeutics, summarizes the current research landscape and its core limitations, and proposes future directions focused on the selection of hard clinical endpoints, dual-pathway benefit assessment, and investigator-initiated trials.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"34 8","pages":"738-742"},"PeriodicalIF":0.0,"publicationDate":"2026-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13529418/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148907123","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Mesenchymal stem cell-derived exosomes: a new hope for metabolic-associated fatty liver disease].","authors":"D Zhou, X Q Gao, L T Zhang","doi":"10.3760/cma.j.cn501113-20250827-00350","DOIUrl":"10.3760/cma.j.cn501113-20250827-00350","url":null,"abstract":"<p><p>Currently, there are clinically limited therapeutic options for metabolic-associated fatty liver disease (MAFLD), and the treatment effect is not optimistic. Mesenchymal stem cell (MSC) therapy for MAFLD shows good application prospects but also possesses certain potential treatment risks. Mesenchymal stem cells can secrete various functional exosomes, which not only retain the therapeutic efficacy of mesenchymal stem cells but also significantly mitigate their associated treatment risks. Mesenchymal stem cell-derived exosomes can play a hepatoprotective, antioxidant, or drug-sensitizing role in liver diseases, with advantages of low immunogenicity and high biocompatibility. Therefore, mesenchymal stem cell-derived exosomes are expected to offer novel therapeutic strategies for the treatment of metabolic-associated fatty liver disease.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"34 8","pages":"811-816"},"PeriodicalIF":0.0,"publicationDate":"2026-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13529432/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148907404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Across-sectional study on the association between steatotic liver disease and its subtypes, cardiovascular health status, and extrahepatic comorbidity].","authors":"J B Guan, R X Yang, J J Yan, Y W Shi, X L He, L Qin, Z Yang, Q Su, J G Fan","doi":"10.3760/cma.j.cn501113-20260609-00241","DOIUrl":"10.3760/cma.j.cn501113-20260609-00241","url":null,"abstract":"&lt;p&gt;&lt;p&gt;&lt;b&gt;Objective:&lt;/b&gt; To investigate the association between steatotic liver disease (SLD) and its clinical subtypes with metabolic syndrome (MetS), type 2 diabetes mellitus (T2DM), hypertension (HTN), chronic kidney disease (CKD), cardiovascular disease (CVD), and extrahepatic malignancies, as well as the impact of cardiovascular health scores on these aforementioned comorbidities. &lt;b&gt;Methods:&lt;/b&gt; A cross-sectional analysis was conducted within a subcohort of the Malignancy Occurrence Risk Epidemiology Study, based on baseline data from the Shanghai Chongming Town Community Residents Cohort (March-November, 2011) among Chinese patients with type 2 diabetes mellitus. Sonographically diagnosed SLD was classified into metabolic-associated fatty liver disease (MASLD), metabolic and alcohol-associated fatty liver disease (MetALD), alcoholic liver disease (ALD), and SLD of other causes according to metabolic cardiovascular risk factors and alcohol consumption. Cardiovascular health status was assessed using the LE8 (Life's Essential 8) score. Intergroup differences were compared using appropriate parametric or nonparametric tests. The association between the prevalence of extrahepatic comorbidities and LE8 scores was analyzed using a multivariate logistic regression models. &lt;b&gt;Results:&lt;/b&gt; The prevalence rates of SLD and its subtypes, MASLD, MetALD, and ALD were 42.15% (4 122/9 779), 39.00% (3 814/9 779), 1.48% (145/9 779), and 1.57% (154/9 779), respectively, among 9 779 subjects aged 40 -70 years. The prevalence rates of T2DM, HTN, CKD, and CVD were significantly higher in the high-risk liver fibrosis index-4 group (FIB-4&gt;2.67) than in the non-high-risk group (&lt;i&gt;P&lt;/i&gt;&lt;0.05). The prevalence rates of T2DM, HTN, CKD, and CVD metabolic disorders were significantly higher in patients with SLD than patients with non-SLD (&lt;i&gt;P&lt;/i&gt;&lt;0.05). MetALD and ALD patients had higher prevalence rates of HTN than patients with MASLD (&lt;i&gt;P&lt;/i&gt;&lt;0.05). All ALD patients had combined metabolic cardiovascular risk factors, with the prevalence rates of MetS, T2DM, HTN, and CVD showing an increasing trend from MASLD to MetALD to ALD. However, no significant differences were observed in the history of extrahepatic malignancies between SLD and non-SLD groups or among subgroups. Multivariate logistic regression analysis revealed that the LE8 score was significantly negatively correlated with T2DM and HTN prevalence rates in the overall population, validating a preventive impact in groups of patients with SLD and non-SLD as well as MASLD (&lt;i&gt;P&lt;/i&gt;&lt;0.05). &lt;b&gt;Conclusion:&lt;/b&gt; Cardiovascular-renal-metabolic diseases impose a substantial burden on patients with SLD, while metabolic disorders are more pronounced among patients with ALD. The development of extrahepatic comorbidities is jointly driven by overnutrition and harmful alcohol consumption in patients with MetALD and ALD. LE8 is beneficial for multidimensional risk assessment and interventions targeting for T2DM and HTN in pa","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"34 8","pages":"757-768"},"PeriodicalIF":0.0,"publicationDate":"2026-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13529422/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148906617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Analysis of epidemiological characteristics and spatial clustering of hepatitis C virus in China from 2018 to 2022].","authors":"S F Fan, J H Zhang, Z H Duan, Z Dai, Q Y He","doi":"10.3760/cma.j.cn501113-20260203-00054","DOIUrl":"10.3760/cma.j.cn501113-20260203-00054","url":null,"abstract":"","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"34 8","pages":"801-806"},"PeriodicalIF":0.0,"publicationDate":"2026-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13529427/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148907106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Interpretation of key updates of the 2026 version of the APASL clinical practice guidelines for the management of chronic hepatitis B].","authors":"H S Liu, X W Ai, Y M Sun, H You","doi":"10.3760/cma.j.cn501113-20260505-00178","DOIUrl":"10.3760/cma.j.cn501113-20260505-00178","url":null,"abstract":"<p><p>The Asia-Pacific region has the heavy burden of chronic hepatitis B. In 2026, the Asia-Pacific Association for the Study of the Liver (APASL) updated its clinical practice guidelines for the management of chronic hepatitis B. The recommendations in this version of the guideline are formulated around focusing 13 core areas: vaccination and universal screening strategies, an established system of progressive treatment goals, pathways for stratified assessment of liver fibrosis based on resource availability, expansion of antiviral therapy indications, and advocacy of proactive treatment strategies. Incorporating metabolic risk factors into long-term care and managing co-existing metabolic dysfunction-associated fatty liver disease at the same time emphasizes shared decision-making between patients and clinicians and the use of new technologies in risk assessment, which optimizes the link between diagnosis and treatment and improves long-term clinical outcomes for patients.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"34 8","pages":"743-747"},"PeriodicalIF":0.0,"publicationDate":"2026-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13529428/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148907369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}